Indivior PLC $INDV Shares Acquired by Profund Advisors LLC

Profund Advisors LLC increased its stake in Indivior PLC (NASDAQ:INDV) by 268.8% during the third quarter, HoldingsChannel.com reports. The fund owned 49,650 shares of the company’s stock after buying an additional 36,188 shares during the period. Profund Advisors LLC’s holdings in Indivior were worth $1,780,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Two Seas Capital LP lifted its holdings in shares of Indivior by 5.5% during the third quarter. Two Seas Capital LP now owns 3,671,072 shares of the company’s stock valued at $131,608,000 after purchasing an additional 191,579 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in Indivior by 129.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 3,540,344 shares of the company’s stock worth $126,921,000 after purchasing an additional 1,999,416 shares in the last quarter. Newtyn Management LLC purchased a new position in Indivior in the 2nd quarter worth about $53,577,000. Hennion & Walsh Asset Management Inc. purchased a new position in Indivior in the 2nd quarter worth about $14,781,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Indivior during the 2nd quarter worth about $7,988,000. 60.33% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have commented on INDV. Zacks Research raised shares of Indivior from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 2nd. Craig Hallum reissued a “buy” rating and issued a $53.00 target price on shares of Indivior in a research report on Tuesday, August 4th. Barclays boosted their price target on shares of Indivior from $43.00 to $45.00 and gave the company an “overweight” rating in a report on Wednesday, October 28th. Wall Street Zen downgraded shares of Indivior from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Finally, Weiss Ratings lowered shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, September 24th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $46.40.

Indivior Trading Up 2.6%

NASDAQ:INDV opened at $36.28 on Tuesday. The firm has a market capitalization of $4.28 billion, a price-to-earnings ratio of 9.53 and a beta of 0.87. Indivior PLC has a 1-year low of $27.68 and a 1-year high of $42.81. The business’s fifty day moving average price is $35.18 and its 200 day moving average price is $35.63.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Thursday, October 29th. The company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.06 by $0.26. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%. The firm had revenue of $356.00 million during the quarter, compared to the consensus estimate of $329.35 million. Equities analysts forecast that Indivior PLC will post 3.66 earnings per share for the current year.

Indivior Dividend Announcement

The business also recently declared a special dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 30th will be given a $8.13 dividend.

Insider Activity

In related news, CAO Woodrow D. Anderson purchased 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The stock was acquired at an average cost of $35.69 per share, for a total transaction of $53,535.00. Following the completion of the acquisition, the chief accounting officer owned 27,638 shares in the company, valued at $986,400.22. This trade represents a 5.74% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.74% of the stock is owned by company insiders.

Indivior Company Profile

Indivior PLC (NASDAQ:INDV) is a global pharmaceutical company focused on developing and commercializing medicines for substance use disorders and serious mental health conditions. Its portfolio is centered on treatments for opioid use disorder, opioid overdose, and related medical needs.

The company’s principal products include Sublocade, an extended-release buprenorphine injection for opioid use disorder; Suboxone, a buprenorphine and naloxone treatment available in film and other formulations; and Opvee, a nalmefene nasal spray intended for the emergency treatment of known or suspected opioid overdose.